4月9日 -
** C4 TherapeuticsCCCC.O股价盘前上涨约8%至3.13美元
** 生物技术公司称，它与瑞士制药商罗氏ROPC.S.签署了一项合作协议，共同开发新的抗癌药物，交易金额可能超过10亿美元
** 补充说，它将获得2000万美元的预付款，并有资格获得与合作成功相关的里程碑付款和特许权使用费
** 与罗氏公司合作开发可分解与癌症有关的有害蛋白质的药物，旨在解决难以治疗的肿瘤问题 - CCCC
** 补充说，罗氏公司将领导 C4 设计候选药物的测试和最终商业投放。
** 交易建立在 2016 年开始的合作基础之上
** 截至上一交易日收盘，股价年累计上涨约 52%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.